Results 11 to 20 of about 831,573 (301)

STING agonist-loaded, CD47/PD-L1-targeting nanoparticles potentiate antitumor immunity and radiotherapy for glioblastoma

open access: yesNature Communications, 2023
Glioblastoma is an immunologically cold tumour, with poor CD8 + T cell infiltration and enrichment in immunosuppressive tumour-associated myeloid cells. Here, the authors generate a bispecific lipid nanoparticle targeting CD47 and PD-L1, combined with a ...
Peng Zhang   +18 more
doaj   +1 more source

Intelligent SERS Navigation System Guiding Brain Tumor Surgery by Intraoperatively Delineating the Metabolic Acidosis

open access: yesAdvancement of science, 2022
Surgeons face challenges in intraoperatively defining margin of brain tumors due to its infiltrative nature. Extracellular acidosis caused by metabolic reprogramming of cancer cells is a reliable marker for tumor infiltrative regions. Although the acidic
Ziyi Jin   +14 more
semanticscholar   +1 more source

Inhibition of secretory leukocyte protease inhibitor (SLPI) promotes the PUMA-mediated apoptosis and chemosensitivity to cisplatin in colorectal cancer cells

open access: yesDiscover Oncology, 2023
Background Aberrant expression of Secretory Leukocyte Protease Inhibitor (SLPI) has been associated with human cancer growth and its suppression was identified as a potential target for anti-cancer drugs, particularly in colorectal cancer.
Zhijiang Wei   +7 more
doaj   +1 more source

Fluorescence-Guided Surgery: A Review on Timing and Use in Brain Tumor Surgery

open access: yesFrontiers in Neurology, 2021
Fluorescence-guided surgery (FGS) allows surgeons to have improved visualization of tumor tissue in the operating room, enabling maximal safe resection of malignant brain tumors.
A. Schupper   +6 more
semanticscholar   +1 more source

Turning on the light for brain tumor surgery: A 5-aminolevulinic acid story

open access: yesNeuro-Oncology, 2022
To aid surgeons in more complete and safe resection of brain tumors, adjuvant technologies have been developed to improve visualization of target tissue.
D. McCracken   +5 more
semanticscholar   +1 more source

CD97 is associated with mitogenic pathway activation, metabolic reprogramming, and immune microenvironment changes in glioblastoma

open access: yesScientific Reports, 2022
Glioblastoma (GBM) is the most common primary brain tumor with a median survival under two years. Using in silico and in vitro techniques, we demonstrate heterogeneous expression of CD97, a leukocyte adhesion marker, in human GBM.
Michael M. Safaee   +15 more
doaj   +1 more source

Applications of indocyanine green in brain tumor surgery: review of clinical evidence and emerging technologies.

open access: yesNeurosurgical Focus, 2021
Indocyanine green (ICG) is a water-soluble dye that was approved by the FDA for biomedical purposes in 1956. Initially used to measure cardiocirculatory and hepatic functions, ICG's fluorescent properties in the near-infrared (NIR) spectrum soon led to ...
Clare W. Teng   +6 more
semanticscholar   +1 more source

Reducing the Cognitive Footprint of Brain Tumor Surgery

open access: yesFrontiers in Neurology, 2021
The surgical management of brain tumors is based on the principle that the extent of resection improves patient outcomes. Traditionally, neurosurgeons have considered that lesions in “non-eloquent” cerebrum can be more aggressively surgically managed ...
N. Dadario   +3 more
semanticscholar   +1 more source

Reducing the burden of brain tumor surgery [PDF]

open access: yesActa Neurochirurgica, 2020
Abstract Background Even though the need has been challenged, admitting patients to an intensive care or medium care unit (ICU/MCU) after adult supratentorial tumor craniotomy remains common practice. We have introduced a “no ICU, unless” policy for tumor craniotomy patients and evaluate costs, complications, and length ...
Mark ter Laan   +3 more
openaire   +3 more sources

Proteomic analysis predicts anti-angiogenic resistance in recurred glioblastoma

open access: yesJournal of Translational Medicine, 2023
Background Recurrence is common in glioblastoma multiforme (GBM) because of the infiltrative, residual cells in the tumor margin. Standard therapy for GBM consists of surgical resection followed by chemotherapy and radiotherapy, but the median survival ...
Hanwool Jeon   +13 more
doaj   +1 more source

Home - About - Disclaimer - Privacy